
Proteomics International Completes Independent Validation of PromarkerEndo to Diagnose Early-Stage Endometriosis
Proteomics International independently validates PromarkerEndo, showing 90% sensitivity for stage IV endometriosis, with commercial availability targeted for FY27.




